Literature DB >> 14515357

Minocycline enhances MPTP toxicity to dopaminergic neurons.

Lichuan Yang1, Shuei Sugama, Jason W Chirichigno, Jason Gregorio, Stefan Lorenzl, Dong H Shin, Susan E Browne, Yoshinori Shimizu, Tong H Joh, M Flint Beal, David S Albers.   

Abstract

Minocycline has been shown previously to have beneficial effects against ischemia in rats as well as neuroprotective properties against excitotoxic damage in vitro, nigral cell loss via 6-hydroxydopamine, and to prolong the life-span of transgenic mouse models of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). We investigated whether minocycline would protect against toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that selectively destroys nigrostriatal dopaminergic (DA) neurons and produces a clinical state similar to Parkinson's disease (PD) in rodents and primates. We found that although minocycline inhibited microglial activation, it significantly exacerbated MPTP-induced damage to DA neurons. We present evidence suggesting that this effect may be due to inhibition of DA and 1-methyl-4-phenylpridium (MPP+) uptake into striatal vesicles. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14515357     DOI: 10.1002/jnr.10709

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  43 in total

Review 1.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

2.  Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.

Authors:  Neal K Bennett; Rebecca Chmielowski; Dalia S Abdelhamid; Jonathan J Faig; Nicola Francis; Jean Baum; Zhiping P Pang; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Biomaterials       Date:  2016-10-04       Impact factor: 12.479

Review 3.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 4.  Remote neurodegeneration: multiple actors for one play.

Authors:  Maria Teresa Viscomi; Marco Molinari
Journal:  Mol Neurobiol       Date:  2014-01-19       Impact factor: 5.590

5.  Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.

Authors:  Eric E Beier; Matthew Neal; Gelerah Alam; Melissa Edler; Long-Jun Wu; Jason R Richardson
Journal:  Neurobiol Dis       Date:  2017-08-18       Impact factor: 5.996

6.  Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats.

Authors:  Harikesh Kalonia; Jitendriya Mishra; Anil Kumar
Journal:  Neurotox Res       Date:  2012-03-06       Impact factor: 3.911

7.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

Review 8.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 9.  Neural and immune mechanisms in the pathogenesis of Parkinson's disease.

Authors:  Fabio Blandini
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-03       Impact factor: 4.147

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.